<?xml version='1.0' encoding='utf-8'?>
<document id="23754514"><sentence text="Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin."><entity charOffset="0-9" id="DDI-PubMed.23754514.s1.e0" text="Darexaban" /><entity charOffset="96-103" id="DDI-PubMed.23754514.s1.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23754514.s1.e0" e2="DDI-PubMed.23754514.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23754514.s1.e0" e2="DDI-PubMed.23754514.s1.e1" /></sentence><sentence text="To investigate the impact of the direct Factor Xa inhibitor darexaban administered in a modified-release formulation (darexaban-MR) on the pharmacokinetic (PK) profile of digoxin"><entity charOffset="60-69" id="DDI-PubMed.23754514.s2.e0" text="darexaban" /><entity charOffset="171-178" id="DDI-PubMed.23754514.s2.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23754514.s2.e0" e2="DDI-PubMed.23754514.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23754514.s2.e0" e2="DDI-PubMed.23754514.s2.e1" /></sentence><sentence text=" In this Phase I, randomized, double-blind, two-period crossover study (8 days for each treatment, 10 days washout), 24 healthy subjects received darexaban-MR 120 mg once/day (qd) + digoxin 0"><entity charOffset="182-189" id="DDI-PubMed.23754514.s3.e0" text="digoxin" /></sentence><sentence text="25 mg qd in one treatment period, and placebo + digoxin 0" /><sentence text="25 mg qd in the other treatment period" /><sentence text=" Blood for PK assessment of digoxin and darexaban was obtained in serial profile on day 8, as well as pre-dose on day 6-7; urinary PK samples were obtained up to 24 h after the last dose on day 8"><entity charOffset="28-35" id="DDI-PubMed.23754514.s6.e0" text="digoxin" /><entity charOffset="40-49" id="DDI-PubMed.23754514.s6.e1" text="darexaban" /><pair ddi="false" e1="DDI-PubMed.23754514.s6.e0" e2="DDI-PubMed.23754514.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23754514.s6.e0" e2="DDI-PubMed.23754514.s6.e1" /></sentence><sentence text=" A lack of interaction was determined if 90 % confidence intervals (CIs) for the geometric mean ratios (GMR) of digoxin C max,ss and AUC0-24h,ss with and without darexaban-MR co-administration were within 0"><entity charOffset="112-121" id="DDI-PubMed.23754514.s7.e0" text="digoxin C" /></sentence><sentence text="80-1" /><sentence text="25 limits" /><sentence text=" Pharmacodynamic activity was assessed by international normalized ratio and activated partial thromboplastin time" /><sentence text=" Twenty-three subjects completed the study" /><sentence text=" The GMR (90 % CI) for C max,ss and AUC0-24h,ss of digoxin plus darexaban versus digoxin plus placebo was 1"><entity charOffset="51-58" id="DDI-PubMed.23754514.s12.e0" text="digoxin" /><entity charOffset="64-73" id="DDI-PubMed.23754514.s12.e1" text="darexaban" /><entity charOffset="81-88" id="DDI-PubMed.23754514.s12.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23754514.s12.e0" e2="DDI-PubMed.23754514.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23754514.s12.e0" e2="DDI-PubMed.23754514.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23754514.s12.e0" e2="DDI-PubMed.23754514.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23754514.s12.e1" e2="DDI-PubMed.23754514.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23754514.s12.e1" e2="DDI-PubMed.23754514.s12.e2" /></sentence><sentence text="03 (90 % CI: 0" /><sentence text="94-1" /><sentence text="12) and 1" /><sentence text="11 (90 % CI: 1" /><sentence text="05-1" /><sentence text="17), respectively" /><sentence text=" The 90 % CI for the GMRs fell within the limits of 0" /><sentence text="80-1" /><sentence text="25, indicating a lack of drug-drug interaction" /><sentence text=" Co-administration of digoxin with darexaban-MR was well tolerated, with no unexpected treatment-emergent adverse events or safety concerns"><entity charOffset="22-29" id="DDI-PubMed.23754514.s22.e0" text="digoxin" /><entity charOffset="35-47" id="DDI-PubMed.23754514.s22.e1" text="darexaban-MR" /><pair ddi="false" e1="DDI-PubMed.23754514.s22.e0" e2="DDI-PubMed.23754514.s22.e0" /><pair ddi="false" e1="DDI-PubMed.23754514.s22.e0" e2="DDI-PubMed.23754514.s22.e1" /></sentence><sentence text=" Co-administration of darexaban-MR did not impact the steady-state PK profile of digoxin"><entity charOffset="81-88" id="DDI-PubMed.23754514.s23.e0" text="digoxin" /></sentence><sentence text="" /></document>